A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of XP13512/GSK1838262 in the Treatment of Patients With Primary Restless Legs Syndrome

STUDY OBJECTIVE: To evaluate the efficacy and tolerability of XP13512/GSK1838262, an investigational nondopaminergic agent for the treatment of moderate-to-severe primary restless legs syndrome (RLS). DESIGN: Randomized, double-blind, placebo-controlled, crossover trial. SETTING: Nine US clinical si...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kushida, Clete A., Walters, Arthur S., Becker, Philip, Thein, Stephen G., Perkins, A. Thomas, Roth, Thomas, Canafax, Daniel, Barrett, Ronald W.
Formato: Artigo
Idioma:Inglês
Publicado: Associated Professional Sleep Societies, LLC 2009
Assuntos:
Restless Legs Syndrome
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2635579/
https://ncbi.nlm.nih.gov/pubmed/19238802
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares